Pharming Group (NASDAQ:PHAR – Get Free Report) had its target price boosted by research analysts at Oppenheimer from $30.00 to $39.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s target price indicates a potential upside of 343.94% from the company’s current price.
Several other equities analysts also recently weighed in on PHAR. HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Friday. Jefferies Financial Group began coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price target on the stock.
Check Out Our Latest Report on Pharming Group
Pharming Group Stock Performance
Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Equities research analysts predict that Pharming Group will post -0.2 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR – Free Report) by 16.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 0.03% of the company’s stock.
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
- Five stocks we like better than Pharming Group
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Stock Splits, Do They Really Impact Investors?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What is diluted earnings per share (Diluted EPS)?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.